Alpha Cognition Inc. Common Stock (ACOG) Stock Price & Analysis
Alpha Cognition Inc. Common Stock (ACOG) closed at USD 8.45 on Thursday, October 15, 2026, down 2.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.65; the Oct 15, 2026 session ranged USD 8.18–8.75 on volume of 225,500 shares. Market capitalization is $184.02M, with a 52-week range of USD 4.5–10.14 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACOG.md
Key facts (ACOG)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (6 analysts), mean target USD 18 (range 12–21).
- Total return with dividends: 1Y +19.7% vs S&P 500 +18.1%; 5Y +57.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.33, revenue estimate $9.9M.
Analysts (ACOG)
Consensus Buy (mean 1.50 on a 1–5 scale), 6 analysts; mean target USD 18 (low 12, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | B. Riley Securities | Initiated | Buy | $21 |
| 2026-08-17 | HC Wainwright & Co. | Target raised | Buy | $18 → $20 |
| 2026-07-10 | Raymond James | Initiated | Outperform | $20 |
Total return (dividends reinvested) (ACOG)
| 1Y (from 2025-10-16) | 5Y (from 2024-11-11) | |
|---|---|---|
| Total return | +19.7% | +57.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +19.8% | +26.5% |
| Volatility (annualized) | 62.7% | 67.2% |
| Max drawdown | -36.9% (Oct 2025→Feb 2026) | -55.3% (Jul 2025→Jan 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 8.45 |
|---|---|
| Change | ▼ 2.31% (down) |
| Previous Close | USD 8.65 |
| Open | USD 8.64 |
| Day Range | USD 8.18 – 8.75 |
| 52-Week Range | USD 4.5 – 10.14 |
| Volume | 225,500 shares |
| Market Cap | $184.02M |
| Exchange | NCM |
Technical Analysis (ACOG)
Nexqual's technical model rates ACOG "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.31 (neutral) |
| vs SMA50 | Below (USD 8.99) |
| MACD | -0.05 (negative) |
Analyst Ratings (ACOG)
Wall Street analysts rate ACOG "Buy" based on 6 analysts, with a mean price target of USD 18 (range USD 12–21), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 18 |
| High Target | USD 21 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ACOG)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $9.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.4 vs est -0.39 ▼ miss |
| 2026-03-31 | USD -0.32 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.43 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (ACOG)
| Total Revenue | $15.26M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +267.60% |
| Gross Margin | +90.38% |
| Operating Margin | -127.29% |
| Profit Margin | -137.70% |
| ROE | -49.53% |
| Current Ratio | 9.03 |
| Total Cash | $41.38M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (ACOG)
Nexqual rates Alpha Cognition Inc. Common Stock's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +268% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $41M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$31M (TTM) |
| Efficiency | Critical — ROE -50%, ROA -30.4% |
Ownership (ACOG)
| Insider Ownership | +5.13% |
|---|---|
| Institutional Ownership | +56.80% |
| Shares Outstanding | 21.78M |
| Float | 10.81M |
| Short % of Float | +1.86% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (ACOG)
Alpha Cognition Inc. Common Stock is led by Michael E. McFadden B.B.A. (age 58), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | Michael E. McFadden B.B.A. (age 58) |
|---|---|
| Founder, Consultant, Corporate Secretary & Director | Kenneth Anthony Cawkell B.A., LL.B. (age 74) |
| VP of Finance & Accounting and Interim CFO | Henry H. Du (age 46) |
| Chief Operating Officer | Lauren D'Angelo (age 47) |
| Chief Scientific Officer | Denis G. Kay M.Sc. (age 68) |
Major Backers & Investors (ACOG)
Notable institutional backers of Alpha Cognition Inc. Common Stock include Opaleye Management Inc., Solas Capital Management, LLC, AWM Investment Company, Inc., according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 13.3% |
| Solas Capital Management, LLC | 8.84% |
| AWM Investment Company, Inc. | 7.68% |
| Cable Car Capital, LP | 6.35% |
| Ikarian Capital, LLC | 3.84% |
| Sphera Funds Management Ltd. | 2.51% |
| Alyeska Investment Group, L.p. | 1.68% |
| Aristides Capital, LLC | 1% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt